Preparations for the commercial launch of a hair growth product are on track, with production cost reduced by over 80% and a cash runway secured into Q2 2026. Financials show improved operating losses year-over-year, and the company is prioritizing cosmetic dermatology projects in large, growing markets.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.